Your browser doesn't support javascript.
loading
Targeted Mass Spectrometry Enables Multiplexed Quantification of Immunomodulatory Proteins in Clinical Biospecimens.
Whiteaker, Jeffrey R; Lundeen, Rachel A; Zhao, Lei; Schoenherr, Regine M; Burian, Aura; Huang, Dongqing; Voytovich, Ulianna; Wang, Tao; Kennedy, Jacob J; Ivey, Richard G; Lin, Chenwei; Murillo, Oscar D; Lorentzen, Travis D; Thiagarajan, Mathangi; Colantonio, Simona; Caceres, Tessa W; Roberts, Rhonda R; Knotts, Joseph G; Reading, Joshua J; Kaczmarczyk, Jan A; Richardson, Christopher W; Garcia-Buntley, Sandra S; Bocik, William; Hewitt, Stephen M; Murray, Karen E; Do, Nhan; Brophy, Mary; Wilz, Stephen W; Yu, Hongbo; Ajjarapu, Samuel; Boja, Emily; Hiltke, Tara; Rodriguez, Henry; Paulovich, Amanda G.
Afiliación
  • Whiteaker JR; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States.
  • Lundeen RA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States.
  • Zhao L; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States.
  • Schoenherr RM; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States.
  • Burian A; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States.
  • Huang D; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States.
  • Voytovich U; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States.
  • Wang T; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States.
  • Kennedy JJ; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States.
  • Ivey RG; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States.
  • Lin C; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States.
  • Murillo OD; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States.
  • Lorentzen TD; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States.
  • Thiagarajan M; Frederick National Laboratory for Cancer Research, Frederick, MD, United States.
  • Colantonio S; Cancer Research Technology Program, Antibody Characterization Lab, Frederick National Laboratory for Cancer Research, Frederick, MD, United States.
  • Caceres TW; Cancer Research Technology Program, Antibody Characterization Lab, Frederick National Laboratory for Cancer Research, Frederick, MD, United States.
  • Roberts RR; Cancer Research Technology Program, Antibody Characterization Lab, Frederick National Laboratory for Cancer Research, Frederick, MD, United States.
  • Knotts JG; Cancer Research Technology Program, Antibody Characterization Lab, Frederick National Laboratory for Cancer Research, Frederick, MD, United States.
  • Reading JJ; Cancer Research Technology Program, Antibody Characterization Lab, Frederick National Laboratory for Cancer Research, Frederick, MD, United States.
  • Kaczmarczyk JA; Cancer Research Technology Program, Antibody Characterization Lab, Frederick National Laboratory for Cancer Research, Frederick, MD, United States.
  • Richardson CW; Cancer Research Technology Program, Antibody Characterization Lab, Frederick National Laboratory for Cancer Research, Frederick, MD, United States.
  • Garcia-Buntley SS; Cancer Research Technology Program, Antibody Characterization Lab, Frederick National Laboratory for Cancer Research, Frederick, MD, United States.
  • Bocik W; Cancer Research Technology Program, Antibody Characterization Lab, Frederick National Laboratory for Cancer Research, Frederick, MD, United States.
  • Hewitt SM; Experimental Pathology Laboratory, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institute of Health, Bethesda, MD, United States.
  • Murray KE; Veteran's Administration (VA) Cooperative Studies Program, Veteran's Administration (VA) Boston Healthcare System (151MAV), Jamaica Plain, MA, United States.
  • Do N; Veteran's Administration (VA) Cooperative Studies Program, Veteran's Administration (VA) Boston Healthcare System (151MAV), Jamaica Plain, MA, United States.
  • Brophy M; Department of Medicine, Boston University School of Medicine, Boston, MA, United States.
  • Wilz SW; Veteran's Administration (VA) Cooperative Studies Program, Veteran's Administration (VA) Boston Healthcare System (151MAV), Jamaica Plain, MA, United States.
  • Yu H; Department of Medicine, Boston University School of Medicine, Boston, MA, United States.
  • Ajjarapu S; Department of Medicine, Boston University School of Medicine, Boston, MA, United States.
  • Boja E; Pathology and Laboratory Medicine Service, Program, Veteran's Administration (VA) Boston Healthcare System, Jamaica Plain, MA, United States.
  • Hiltke T; Pathology and Laboratory Medicine Service, Program, Veteran's Administration (VA) Boston Healthcare System, Jamaica Plain, MA, United States.
  • Rodriguez H; Department of Pathology, Harvard Medical School, Boston, MA, United States.
  • Paulovich AG; Veteran's Administration (VA) Cooperative Studies Program, Veteran's Administration (VA) Boston Healthcare System (151MAV), Jamaica Plain, MA, United States.
Front Immunol ; 12: 765898, 2021.
Article en En | MEDLINE | ID: mdl-34858420
Immunotherapies are revolutionizing cancer care, producing durable responses and potentially cures in a subset of patients. However, response rates are low for most tumors, grade 3/4 toxicities are not uncommon, and our current understanding of tumor immunobiology is incomplete. While hundreds of immunomodulatory proteins in the tumor microenvironment shape the anti-tumor response, few of them can be reliably quantified. To address this need, we developed a multiplex panel of targeted proteomic assays targeting 52 peptides representing 46 proteins using peptide immunoaffinity enrichment coupled to multiple reaction monitoring-mass spectrometry. We validated the assays in tissue and plasma matrices, where performance figures of merit showed over 3 orders of dynamic range and median inter-day CVs of 5.2% (tissue) and 21% (plasma). A feasibility study in clinical biospecimens showed detection of 48/52 peptides in frozen tissue and 38/52 peptides in plasma. The assays are publicly available as a resource for the research community.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Péptidos / Manejo de Especímenes / Espectrometría de Masas / Cromatografía Liquida / Proteoma / Proteómica Límite: Humans Idioma: En Revista: Front Immunol Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Péptidos / Manejo de Especímenes / Espectrometría de Masas / Cromatografía Liquida / Proteoma / Proteómica Límite: Humans Idioma: En Revista: Front Immunol Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Suiza